#USA #American Injectables #Travis Allen #Kimberlee Steele #Brooksville, Florida

American Injectables Unveils Key Leadership Changes

American Injectables, a prominent contract development and manufacturing organization (CDMO), has announced significant leadership appointments designed to propel the company forward in 2025. As the demand for domestic pharmaceutical production continues to surge, these strategic shifts come at a critical juncture.

Travis Allen, a foundational member of American Injectables since its inception, has been appointed as the new Chief Executive Officer and Board Director. Formerly the CEO of Endo International and Par Pharmaceutical, Paul Campanelli will transition to the role of Executive Chairman. Additionally, Kimberlee Steele, previously Managing Director of North America at SHL Medical, joins the board, bringing over two decades of experience from the pharmaceutical and medical device sectors.

In his new role, Allen expressed pride in leading a company focused on delivering dependable results for its clients. “This transition is the culmination of a long-term strategy that we have been developing,” he stated. With a Pharm.D. background and extensive knowledge in operations and business development, Allen has been pivotal in expanding the company’s sterile injectable capabilities. He played an essential role in both business development within the 503B outsourcing sector and the establishment of a commercial sterile injectables facility. This unique blend of experience equips him to tackle industry challenges while delivering value to the market.

The transition to leadership roles for both Campanelli and Steele signals a robust future for American Injectables. Campanelli, a seasoned expert in sterile products, has been with the company’s board since March 2024 and is well-qualified to step into the Executive Chairman role, where he will leverage his extensive network and insights to guide strategic initiatives. Meanwhile, Steele's past leadership experience at companies such as Catalent highlights her strategic insight across a variety of drug technologies, including biologics and cell therapies.

Steele remarked on her excitement for the new role: “American Injectables’ dedication to transparency and customer-centric approaches aligns with the evolving needs of our industry. I look forward to contributing to the company's next growth phase.”

These appointments are especially significant following American Injectables' recent FDA approval and its ongoing efforts to enhance its manufacturing capabilities in sterile injectables. The newly strengthened leadership team is dedicated to driving operational excellence and scaling product offerings to meet increasing industry demands while ensuring the highest quality standards.

About American Injectables

Operating as a privately held CDMO, American Injectables specializes in the production of ready-to-use glass and plastic vials as well as nested syringes. Beyond manufacturing, the organization excels in formulation optimization, analytical and stability services, and process engineering. With a focus on strategic partnerships and individualized timelines, their services cater to both U.S. and international markets, establishing them as a key player in the pharmaceutical landscape. To learn more about their offerings, visit americaninj.com or connect with them on LinkedIn.